Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Voyager Technologies CEO Dylan Taylor discusses the booming commercial space race, NASA partnerships, defense tech, and building the future beyond Earth.
Inflation is outrunning growth, squeezing consumers and raising fear of a summer slowdown as high rates and sticky prices test spending and markets today now.
TIME's editorial director Emma Barker unpacks the 2026 100 Most Influential Companies list, spotlighting trends, AI impact, surprises, and leadership shifts.
From dire wolves to new species targets, scientists at Colossal Biosciences are using gene editing to revive extinction and reshape biodiversity as we know it.
R.J. Hottovy, Head of Analytical Research at Placer.ai, breaks down restaurant trends, pricing power, and which chains are winning this earnings season.
